Tacrolimus 0.1% versus ciclopiroxolamine 1% for maintenance therapy in patients with severe facial seborrheic dermatitis: A multicenter, double-blind, randomized controlled study.
Joly P, Tejedor I, Tetart F, Cailleux HC, Barrel A, De Preville PA, Mion-Mouton N, Gabison G, Baricault S, Tordeur CG, Dore MX, Rossi B, Bourseau-Quetier C, Chamaillard M, Ly S, Chosidow O, Richard-Lallemand MA, Rzeznik JC, Amici JM, Lair G, Bechu S, Benichou J, Thill C, Beylot-Barry M.
Joly P, et al. Among authors: baricault s.
J Am Acad Dermatol. 2021 May;84(5):1278-1284. doi: 10.1016/j.jaad.2020.09.055. Epub 2020 Sep 30.
J Am Acad Dermatol. 2021.
PMID: 33010323
Clinical Trial.